Pharmaceutical & Medical Device Development

Postgraduate study:
Master’s degree, Graduate Diploma and Graduate Certificate

Professional Medical Education
"Completing this course will hold you in good stead for employment within the pharmaceutical industry in Australia."

Karen Whitelock
County Patient Safety Head, Novartis
Welcome from the Course Leader

I am delighted to introduce you to our new postgraduate coursework degree in Pharmaceutical & Medical Device Development. My colleagues and I have developed a Graduate Certificate, Graduate Diploma and Master’s degree to help prepare you to develop drugs and devices and navigate the significant regulatory control of these products. They are designed to meet the requirements of those working or planning to work in the pharmaceutical and medical device areas.

As this is an industry focused program it has been developed in partnership with leaders in the field – in academia, regulatory affairs, industry associations as well as a wide array of industry organisations. We have been overwhelmed by the generosity of our contributors, who have been keen to address the urgent and unmet need to upskill the workforce in the areas covered by this program. The coursework can be tailored to your requirements and is suitable for health, science and engineering graduates. The higher degrees offer the opportunity to develop your skills in areas such as research, health economics, Pharma R&D and regulation.

Please feel free to approach us if you have any questions about the degrees. I look forward to working with you.

Paul M Young

Professor of Respiratory Technology,
Discipline of Pharmacology
Sydney Medical School
Deputy Director and Head of Respiratory Technology
Woolcock Institute of Medical Research

Learn more online at:
sydney.edu.au/medicine/study/postgraduate/pharmaceutical-medical-device-development.php
About
Pharmaceutical & Medical Device Development:
Graduate Certificate, Graduate Diploma, Master’s degree

These new fully online degrees will provide education and guidance in the complex pharmaceutical and device regulatory sectors. The program is flexible, with online delivery designed to support the learning of busy professionals. You will gain a thorough knowledge of the process of translating a new drug, formulation or medical device, from a laboratory setting to a final approved product. Building on this, you will develop the critical thinking needed to transform a new therapeutic drug or device into a commercially viable product. The program offers a unique opportunity to learn from industry experts.

This program is for graduates from a health, medical or science-related discipline who currently work, or plan to work, in the pharmaceutical, medical device or regulatory industries.

Taught by leading minds in the field
The program is taught by industry professionals, regulatory body leaders, representatives of industry associations and academics. Our multidisciplinary team covers the breadth of career-paths and expertise required for the development, registration and provision of medicines and medical devices in Australia and internationally. Our educators come from a cross-section of organisations within the sector. These include dynamic start-up companies, small/medium enterprises, large pharma, regulatory body (TGA) and industry bodies such as the RACI, MTAA and ARCS.

Advisory Committee
Designed by the pharmaceutical and device sector FOR the pharmaceutical and device sector

Our degrees have been designed to make you work ready and effective. This has been achieved through an extensive consultation process and engagement with stakeholders in the field. Our Advisory Committee members are from numerous industry bodies, pharmaceutical companies and the Therapeutic Goods Administration. This dynamic committee has overseen the development of this degree from its inception, to ensure that graduating students will meet the requirements and expectations of the field. The Committee, along with their industry-based colleagues, have made an ongoing commitment to the development and delivery of these degrees.
Admission requirements

The Graduate Certificate and Graduate Diploma require either a bachelor’s degree or postgraduate degree in a health or science-related discipline (including engineering), or a medical degree. The master’s degree requires you to have a bachelor’s or postgraduate degree in a health or science-related discipline (including engineering) with first-class or second-class honours; a pass bachelor’s degree in a health-related discipline plus work experience; or a medical degree.

The advanced option provides an opportunity to undertake research and is only available to those who have completed the Master’s degree with a weighted average mark of at least 75 percent in 24 credit points of compulsory and/or stream-specific units of study.

<table>
<thead>
<tr>
<th>Program</th>
<th>Credit Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graduate Certificate</td>
<td>24</td>
</tr>
<tr>
<td>Graduate Diploma</td>
<td>36</td>
</tr>
<tr>
<td>Master</td>
<td>48</td>
</tr>
<tr>
<td>Advanced Master</td>
<td>60</td>
</tr>
</tbody>
</table>

How will you study?
You can choose the degree that suits your needs: graduate certificate, graduate diploma or master’s. Most of the coursework is delivered online with an opportunity to work on a final scientific dossier in small groups. If you are working full-time, consider undertaking 1 or 2 units of study per semester. Only part-time study is available in 2017.

Course Fees
Students are charged per unit of study and invoiced each semester.

Enquiries and how to apply
Compulsory units of study

Introduction to Clinical Epidemiology - CEPI5100
This unit introduces the concept of clinical epidemiology and provides students with core skills at an introductory level.

Pharm & medical device development - PCOL5104 (available 2018)
This capstone unit will develop the critical thinking needed to transform a new therapeutic drug or device into a commercially viable product.

Stream specific units of study

Drugs & devices: R&D to registration - PCOL5101
This unit provides foundation knowledge of the process of translating a new drug, formulation and/or delivery device from a laboratory setting to a final approved product.

Modern therapeutics and medical devices - PCOL5102
This unit will develop your understanding and knowledge in current state-of-the-art therapeutic technologies.

Industrial Therapeutics (project) - PCOL5103 (available 2018)
Candidates will work on a project in a specific area.

Medicines policy, economics and ethics - BETH5209
In this unit, we explore and critique global and national policies and processes related to medicine, examining how research and development agendas are set, how medicines are assessed and evaluated, and how new technologies are translated into practice.

Trial design and methods - CLTR5001
This unit of study will focus on the strengths and weaknesses of different clinical study designs.

Elective units

Bioethics, law and society - BETH5104
Health indicators and health surveys - BSTA5003
Quality and safety in healthcare - CEPI5200
Diagnostic and screening tests - CEPI5312
Advanced trial design - CLTR5004
Economics and finance for health policy - HPOL5001
Introductory biostatistics - PUBH5018
Health and risk communication - PUBH5422
**Academic Leads:**

**Professor Paul Young | Course Leader**
Paul is Professor of Respiratory Technology in the Sydney Medical School at the University of Sydney. His team focuses on developing advanced drug delivery systems for treating a wide range of respiratory disorders ranging from asthma to tuberculosis. Paul has 20 years' experience in the Pharmaceutical Industry and comes from an industrial pharmaceutical background. He holds an honours degree in Chemistry (UWE, UK) and PhD in Pharmaceutical Sciences (University of Bath, UK). Paul has an interest in all areas of the pharmaceutical sector, in particular dosage form design, scalability and manufacturing logistics, clinical trials and end-product batch-to-batch and processing problem solving. He has authored 188 peer reviewed papers and has received several large grants.

**Dr Hui Xin Ong (YY) | Course Coordinator (Joint)**
Hui Xin is an Lecturer in the Discipline of Pharmacology, Sydney Medical School and a postdoctoral fellow at the Woolcock Institute. She holds an honours degree in Pharmacy and a PhD in Pharmaceutical Sciences from the University of Sydney. She was a European Respiratory Society-European Lung Foundation Fellow and has worked with diverse experts from academia and industry partners leading to advancement and development of various pharmaceutical formulations.

**Professor Daniela Traini | Course Coordinator (Joint)**
Daniela is Professor in Respiratory Science in Sydney Medical School. She has extensive experience in both academic and industrial pharmaceutics, and retains strong links with the pharmaceutical industry. She has published over 175 peer reviewed papers, holds 5 patents and has attracted more than $12 million in competitive funding. Daniela’s background is in both device and medicine engineering with a specific focus on respiratory research and development.
Advisory Committee: regulatory affairs

**John Skerritt | Deputy Secretary | TGA**

Professor Skerritt joined the Department of Health in 2012 and is Deputy Secretary for Health Products Regulation. The Health Products Regulation Group comprises the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC). John is responsible for leading the design and implementation of broad-ranging reforms to the medicines and medical devices regulatory framework and developing a new regulatory framework for medicinal cannabis in Australia.

Professor Skerritt has extensive experience in regulation, research management, technology application and commercialisation. During the 1990s he held senior management positions in CSIRO and Cooperative Research Centres. He has significant experience on boards of international and national organisations and has more than 25 years of experience in negotiating and leading international technical and commercial collaborations. He is the author of 10 patents and almost 300 refereed scientific publications and is a Thomson-Reuters highly cited researcher.

John is an Adjunct Professor of the Universities of Queensland and Canberra, has a PhD from the University of Sydney, and is a graduate of the Senior Executive Programs of London Business School and of the International Institute for Management Development (IMD) Business School in Switzerland. He was elected a Fellow of the Academy of Technological Sciences and Engineering and a Fellow of the Institute of Public Administration of Australia (Vic).
Advisory Committee:

industry bodies

Shanny Dyer | CEO | ARCS Australia

Shanny is CEO of ARCS Australia Ltd. Shanny has years of experience in the healthcare and therapeutics industry. She is an experienced senior executive, having held roles across industry, government and universities. She has expertise in public administration and policy development with strong corporate governance skills. Over the last ten years Shanny has been involved in many biotech developments and still holds directorships with Wavefront Biometric Technologies Pty Ltd, Seagull Technology Pty Ltd and Bionic Vision Australia Pty Ltd. Shanny also has honorary positions as: Member of the R&D Taskforce; Panel member for NHMRC Development Grants; Panel member for ARCS Industrial Transformation Grants; Member of steering committee reviewing impact of University Research; Member of steering committee for the Australia and New Zealand Rheumatic Fever Vaccine development. Shanny is passionate about professional development and the healthcare sector.

Val Theisz | Director Regulatory Affairs | Medical Technology Association of Australia (MTAA)

Val is a Regulatory Affairs professional with over 15 years experience with medical devices, including life-sustaining, high risk active implantables. She has a masters degree in electrical engineering and holds Regulatory Affairs Certification credentials for EU and US regulations (RAC EU, RAC US) from the US-based Regulatory Affairs Professionals Society (RAPS). Val's experience within the field covers the entire product lifecycle: regulatory strategy; verification and validation (V&V); testing and compliance to international standards; clinical trials; submissions and pre-market approvals in established markets (CE Marking, FDA 510k and PMA, TGA registration, Health Canada licences); and post-market ongoing compliance. Her experience spans the major markets (EU, USA, Australia and Canada).

Val's specialties include: medical device design evaluation; QA systems auditor to ISO 13485; adverse events and recalls; regulatory information management including electronic document management systems (EDMS) and e-submissions. Val Theisz is the author of the book ‘Medical Device Regulatory Practices: An International Perspective’ available through CRC press.
David Edmonds | Principal |  
CMC Regulatory & Royal Australian Chemical Institute (RACI)  
David has more than 45 years experience in the therapeutic goods industry, having worked in manufacturing and QA roles at Sterling Pharmaceuticals, Lilly Industries and A.H. Robins. He spent over 20 years in the R&D company, Peptech Limited as QA and Regulatory manager and since 2008 has been a consultant. David serves and has served on voluntary committees involving therapeutic goods including membership/Chair of RACI Pharmaceutical Science Group (NSW) 1987-present and Associate member Pharmacopoeial Sub-committee of the Joint Interim Expert Advisory Committee on Standards 2005 – 2007.

Jonathan Wojciechowski | Chair, Young Chemists Group NSW | RACI  
Jonathan Wojciechowski is Chair of the Young Chemists Group (YCG) of the Royal Australian Chemical Institute (RACI). Jonathan is a PhD student and research scientist at the University of New South Wales, working in the area of supramolecular chemistry and nanomedicine. He is passionate about research and the translation of ideas into therapeutic goods. As Chair of the YCG, he promotes career development and pathways for young scientists working within the field.
Advisory Committee:
industry

Alan Robertson | Chief Executive Officer | Alsonex
Alan was the CEO and MD of Pharmaxis Ltd for 14 years. He was responsible for raising more than $350 million in the US, Europe and Australia. In that role, he oversaw the development to marketing authorisation of a new inhaled dry powder treatment for cystic fibrosis (Bronchitol) and a bronchial challenge test for hyperactive airway disease (Aridol). He also built a drug discovery capability within Pharmaxis and participated in the creation of PXS4728 – now licensed to Boehringer Ingelheim for the treatment of NASH. He was the CEO of Promics Ltd (now part of Teva) and developed the first C5a receptor antagonist for patients with rheumatoid arthritis. While head of drug discovery at Kinacia, he invented KN-309, a PI3 kinase inhibitor (subsequently licensed to Astra Zeneca). He is a former member of the scientific advisory board of Xenome Limited, a former Non-Executive Director of Patrys Limited and is a current non-executive director of Advent Ltd. As a Senior Scientist at Wellcome PLC, he developed the anti-migraine drug Zomig.

Roman Greifeneder | Executive Director | CathRx
Roman was appointed as an Executive Director of the company in 2014 and is the Chief Operating Officer of CathRx. He has extensive experience in Design and Operations Management, with a focus on new product development/introduction, technology development, technology transfer, manufacturing, engineering, and quality assurance. Roman has over 20 years of experience in the medical device sector. Before joining CathRx, he served as Vice President of Operations for the international medical device company Ventracor Limited. His prior roles included World Class Manufacturing/Engineering Manager of ResMed Limited, and the global leader in sleep apnoea devices, and new product introduction engineer at Telectronics Cardiac Pacing Systems.
Alan Taylor | Executive Chairman | Clarity Pharmaceuticals

Alan has been Executive Chairman of Clarity Pharmaceuticals since 2013. Clarity is a radiopharmaceutical company focused on the development of new treatments for cancer and other serious diseases.

Dr Taylor has a background as a scientist, investment banker, entrepreneur and investor. For the last 3 years, he has been active in the Australian start-up area. Prior to this, Alan spent about 10 years in investment banking with a focus on the life sciences sector. He was an executive director and shareholder of Inteq Limited, a boutique Australian investment bank, where he remains on the Board of Directors. He has significant experience in capital raisings, M&A and general corporate advisory with a focus on small to medium-sized companies. Alan holds an Applied Science degree from the University of Sydney where he won the University Medal. He completed a PhD in Medicine at the Garvan Institute of Medical Research and a Graduate Diploma in Applied Finance at the Securities Institute of Australia.

Nessa Banville | Senior Scientific Liaison | Roche

Nessa Banville completed a PhD, focusing on COPD and Cystic Fibrosis from the Royal College of Surgeons, in Ireland. She continued her post-doc work at the Woolcock Institute of Medical Research in Sydney where she worked on ex-transplant lungs from patients with interstitial lung diseases, including IPF. Nessa joined the pharmaceutical industry in 2014 as a respiratory medical science liaison for GSK focusing on external engagement activities and recently moved to Roche Pharmaceuticals as a senior medical science liaison in the respiratory therapeutic area.
Gary Phillips | Chief Executive Officer | Pharmaxis

Gary is Chief Executive Officer and Board Member of Pharmaxis, where he has worked in various roles since 2003. Pharmaxis is an Australian pharmaceutical research company with a portfolio that includes respiratory products (Bronchitol and Aridol) and a research pipeline focused on areas of high unmet clinical need. He has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products. He worked as area manager for Novartis, responsible for 9 countries in Asia Pacific before joining Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a Bpharm with Honours from Nottingham University in the UK and an MBA from Henley Management College.

Andrew Weekes | Medical Director | GSK

Andrew is Medical Director of GSK Australia. He is a pharmaceutical physician with over fifteen years’ experience across international head office and national subsidiary roles. He has a strong track record as a collaborative and innovative member of executive teams and has lead large multifunctional departments within the Pharmaceutical sector. Andrew has a strong commercial acumen, he has consistently focused on generation, interpretation and communication of evidence to support patients and health care professionals. He has a significant interest in talent development and retention within the industry.
Karen Whitelock | County Patient Safety Head | Novartis
Karen graduated from the University of Sydney and is a registered pharmacist. After working in retail pharmacy for 10 years, she moved to Birmingham, Alabama where she trained hospital pharmacy technicians. Karen completed postgraduate studies in 1993, receiving a Fellowship from the Australian College of Pharmacy Practice. In 1994, she was appointed to Sydney’s Concord Hospital as the inaugural HIV/AIDS Hospital Pharmacist and later as a clinical trials pharmacist.

Karen moved into the pharmaceutical industry in 2001, firstly to Omnicare Clinical Research, then worked in quality at Pfizer, before moving into pharmacovigilance leadership roles, firstly at Sanofi and now at Novartis.

William Glover | NPI Project Manager | Phebra
William completed his PhD in Pharmacy at the University of Sydney. He has worked in drug formulation at Nanomaterials Technology and as a medical scientist at GSK. He has been a quality control manager for various companies including Phebra and GSK.
For more information

Course Coordinator | Paul Young
Sydney Medical School | School of Medical Sciences
T +61 2 9114 0350 |
E paul.young@sydney.edu.au

General Enrolment Enquiries | Amanda Turner
Education Support Officer, Professional Medical Education
T +61 2 9351 1964 |
E a.turner@sydney.edu.au
